.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,478,578

« Back to Dashboard

Summary for Patent: 5,478,578

Title: Powders for inhalation
Abstract:In order to control and optimize the amount of inhalable active substance released when drugs are administered as inhalation powders, the invention calls for the use of auxiliaries consisting of mixtures of coarser particles (average particle size>20 .mu.m) and finer particles (average particle size<10 .mu.m).
Inventor(s): Arnold; Klaus (Ingelheim am Rhein, DE), Grass; Peter (Ingelheim am Rhein, DE), Knecht; Adolf (Freiburg, DE), Roos; Robert (Ingelheim am Rhein, DE), Sluke; Gerhard (Ingelheim am Rhein, DE), Thieme; Herbet (Ingelheim am Rhein, DE), Wenzel; Joachim (Ingelheim am Rhein, DE)
Assignee: Boehringer Ingelheim KG (Ingelheim am Rhein, DE)
Application Number:08/244,737
Patent Claim Types:
see list of patent claims
Composition;
Patent PDF download available with subscription

No matches for this query

Foreign Priority and PCT Information for Patent: 5,478,578

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany41 40 689.3Dec 10, 1991
PCT Information
PCT FiledDecember 12, 1992PCT Application Number:PCT/EP92/02814
PCT Publication Date:June 24, 1993PCT Publication Number: WO93/11746

International Patent Family for Patent: 5,478,578

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria164060<disabled in preview>
Australia3085492<disabled in preview>
Australia670555<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc